Latest Natural Products News

The Calmer Co. has secured a long-term supply agreement for premium noble kava from Papua New Guinea and Vanuatu, underpinning its manufacturing growth and diversified Pacific sourcing network.

The Calmer Co. has signed a binding heads of agreement with Kaiming Agro Processing to establish a long-term manufacturing partnership, leveraging advanced extraction technology in Fiji to scale its premium botanical ingredients business globally.

Cobram Estate Olives has wrapped up a smaller 2026 Australian olive harvest amid natural production cycles and flagged legal challenges over its California Olive Ranch acquisition, while integration efforts progress.

The Calmer Co. has won Coles' approval for its innovative Fiji Kava® FZZR™ product, extending its Australian supermarket reach while gearing up for a broader U.S. retail rollout supported by a key brokerage partnership.

Bio-Gene has signed a term sheet with Sumitomo Corporation and Nakashima Trading to introduce its 100% natural insecticide Qcide® to Japan’s $1 billion household pest market, aiming for a late 2026 launch.

The Calmer Co. International Limited’s Fiji subsidiary has secured a FJ$548k non-repayable grant to expand ready-to-drink production and upgrade supply chain infrastructure, accelerating its growth without diluting shareholder equity.

Skin Elements Limited has marked a pivotal quarter with a $2.5 million capital raise and successful product evaluations, setting the stage for commercial rollout of its natural biotechnology range in 2026.

Skin Elements Limited reports successful completion of key product evaluations and secures $2.5 million placement to fuel growth and commercialisation in 2026.

Echelon Resources reported a solid quarter with production gains at Maari and Mahato fields, supported by new wells and a strategic gas sales agreement, while maintaining shareholder returns through dividends.

Skin Elements Limited has locked in $2.5 million through a two-tranche placement to accelerate the commercial rollout of its SE Formula biotechnology products, offering investors discounted shares and options.

The Calmer Co International Limited has reported its strongest quarterly revenue ever at $2.4 million, driven by robust Australian retail sales and expanding US market presence. The company is also advancing a $1.4 million convertible note to fuel growth and inventory expansion.

The Calmer Co. has secured $700,000 in the first tranche of a $1.4 million convertible note raise, welcoming US distributor Applied Food Sciences as a strategic investor to fuel its expanding wholesale presence.